The European Medicines Agency has recommended granting pan-EU approval to Almirall/Eli Lilly’s eczema drug Ebglyss (lebrikizumab) and Novartis’s protein kinase inhibitor Finlee (dabrafenib) for the treatment of glioma, a type of brain tumor.
However, it has recommended against renewing the conditional marketing authorization of two drugs – PTC Therapeutics’ Translarna (ataluren) for treating patients with Duchenne muscular dystrophy, and
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?